Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Ernest Mario sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $3.57, for a total value of $35,700.00. Following the completion of the sale, the director now owns 10,000 shares of the company’s stock, valued at $35,700. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Ernest Mario also recently made the following trade(s):
- On Thursday, December 14th, Ernest Mario sold 1,967 shares of Tonix Pharmaceuticals stock. The shares were sold at an average price of $3.58, for a total value of $7,041.86.
- On Thursday, December 21st, Ernest Mario sold 36,967 shares of Tonix Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total value of $129,754.17.
Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded up $0.07 on Friday, hitting $3.52. The stock had a trading volume of 65,775 shares, compared to its average volume of 58,735. The firm has a market cap of $26.91, a P/E ratio of -0.74 and a beta of 2.92. Tonix Pharmaceuticals Holding Corp. has a 12 month low of $2.85 and a 12 month high of $9.40.
Several analysts have recently commented on TNXP shares. ValuEngine upgraded Tonix Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Aegis restated a “buy” rating on shares of Tonix Pharmaceuticals in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Tonix Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $8.33.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.